86 related articles for article (PubMed ID: 12535206)
1. Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo.
Halaschek-Wiener J; Kloog Y; Wacheck V; Jansen B
J Invest Dermatol; 2003 Jan; 120(1):109-15. PubMed ID: 12535206
[TBL] [Abstract][Full Text] [Related]
2. Novel Ras antagonist blocks human melanoma growth.
Jansen B; Schlagbauer-Wadl H; Kahr H; Heere-Ress E; Mayer BX; Eichler H; Pehamberger H; Gana-Weisz M; Ben-David E; Kloog Y; Wolff K
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14019-24. PubMed ID: 10570191
[TBL] [Abstract][Full Text] [Related]
3. E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition.
Blum R; Nakdimon I; Goldberg L; Elkon R; Shamir R; Rechavi G; Kloog Y
Int J Cancer; 2006 Aug; 119(3):527-38. PubMed ID: 16496386
[TBL] [Abstract][Full Text] [Related]
4. Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice.
Jansen B; Heere-Ress E; Schlagbauer-Wadl H; Halaschek-Wiener J; Waltering S; Moll I; Pehamberger H; Marciano D; Kloog Y; Wolff K
J Mol Med (Berl); 1999 Nov; 77(11):792-7. PubMed ID: 10619439
[TBL] [Abstract][Full Text] [Related]
5. RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma.
Jiang C; Song T; Li J; Ao F; Gong X; Lu Y; Zhang C; Chen L; Liu Y; He H; Huang O
Mol Neurobiol; 2017 Jan; 54(1):779-787. PubMed ID: 27021020
[TBL] [Abstract][Full Text] [Related]
6. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.
Thallinger C; Wolschek MF; Wacheck V; Maierhofer H; Günsberg P; Polterauer P; Pehamberger H; Monia BP; Selzer E; Wolff K; Jansen B
J Invest Dermatol; 2003 Jun; 120(6):1081-6. PubMed ID: 12787138
[TBL] [Abstract][Full Text] [Related]
7. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
Smalley KS; Eisen TG
Int J Cancer; 2003 Jun; 105(2):165-75. PubMed ID: 12673674
[TBL] [Abstract][Full Text] [Related]
8. Analgesic potential of intrathecal farnesyl thiosalicylic acid and GW 5074 in vincristine-induced neuropathic pain in rats.
Jaggi AS; Singh N
Food Chem Toxicol; 2012 May; 50(5):1295-301. PubMed ID: 22326968
[TBL] [Abstract][Full Text] [Related]
9. Functional inhibition of Ras by S-trans,trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice.
George J; Afek A; Keren P; Herz I; Goldberg I; Haklai R; Kloog Y; Keren G
Circulation; 2002 May; 105(20):2416-22. PubMed ID: 12021230
[TBL] [Abstract][Full Text] [Related]
10. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice.
Weisz B; Giehl K; Gana-Weisz M; Egozi Y; Ben-Baruch G; Marciano D; Gierschik P; Kloog Y
Oncogene; 1999 Apr; 18(16):2579-88. PubMed ID: 10353601
[TBL] [Abstract][Full Text] [Related]
11. Stringent structural requirements for anti-Ras activity of S-prenyl analogues.
Aharonson Z; Gana-Weisz M; Varsano T; Haklai R; Marciano D; Kloog Y
Biochim Biophys Acta; 1998 Feb; 1406(1):40-50. PubMed ID: 9545527
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.
Badar T; Cortes JE; Ravandi F; O'Brien S; Verstovsek S; Garcia-Manero G; Kantarjian H; Borthakur G
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):433-438.e2. PubMed ID: 25795639
[TBL] [Abstract][Full Text] [Related]
13. Ras antagonist inhibits growth and chemosensitizes human epithelial ovarian cancer cells.
Beiner ME; Niv H; Haklai R; Elad-Sfadia G; Kloog Y; Ben-Baruch G
Int J Gynecol Cancer; 2006; 16 Suppl 1():200-6. PubMed ID: 16515591
[TBL] [Abstract][Full Text] [Related]
14. Salirasib (farnesyl thiosalicylic acid) for brain tumor treatment: a convection-enhanced drug delivery study in rats.
Goldberg L; Ocherashvilli A; Daniels D; Last D; Cohen ZR; Tamar G; Kloog Y; Mardor Y
Mol Cancer Ther; 2008 Nov; 7(11):3609-16. PubMed ID: 19001442
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist.
Egozi Y; Weisz B; Gana-Weisz M; Ben-Baruch G; Kloog Y
Int J Cancer; 1999 Mar; 80(6):911-8. PubMed ID: 10074926
[TBL] [Abstract][Full Text] [Related]
16. Ras chaperones: new targets for cancer and immunotherapy.
Kloog Y; Elad-Sfadia G; Haklai R; Mor A
Enzymes; 2013; 33 Pt A():267-89. PubMed ID: 25033809
[TBL] [Abstract][Full Text] [Related]
17. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
18. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
Rotblat B; Ehrlich M; Haklai R; Kloog Y
Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183
[TBL] [Abstract][Full Text] [Related]
19. Single-cell RNA sequencing reveals the mechanism of sonodynamic therapy combined with a RAS inhibitor in the setting of hepatocellular carcinoma.
Wu B; Yuan Y; Liu J; Shang H; Dong J; Liang X; Wang D; Chen Y; Wang C; Zhou Y; Jing H; Cheng W
J Nanobiotechnology; 2021 Jun; 19(1):177. PubMed ID: 34118951
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells.
Du R; Sullivan DK; Azizian NG; Liu Y; Li Y
BMC Cancer; 2021 Mar; 21(1):237. PubMed ID: 33676427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
